BRPI0810439A2 - Formulações farmacêuticas contendo derivados de ácido lipóico - Google Patents

Formulações farmacêuticas contendo derivados de ácido lipóico

Info

Publication number: BRPI0810439A2
Authority: BR; Brazil
Prior art keywords: acid derivatives; pharmaceutical formulations; formulations containing; lipoic acid; containing lipoic
Prior art date: 2007-04-18

Application number

BRPI0810439-5A2A

Other languages

English (en)

Inventor

Robert G I Shorr

Rajinder Bhasin

Robert J Rodriguez

Original Assignee

Cornerstone Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-04-18

Filing date

2008-04-17

Publication date

2014-10-07

2008-04-17 Application filed by Cornerstone Pharmaceuticals Inc filed Critical Cornerstone Pharmaceuticals Inc

2014-10-07 Publication of BRPI0810439A2 publication Critical patent/BRPI0810439A2/pt

2021-06-29 Publication of BRPI0810439B1 publication Critical patent/BRPI0810439B1/pt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/541—Organic ions forming an ion pair complex with the pharmacologically or therapeutically active agent
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Oil, Petroleum & Natural Gas (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Hematology (AREA)
Oncology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Compounds Containing Sulfur Atoms (AREA)
Medicinal Preparation (AREA)

BRPI0810439-5A 2007-04-18 2008-04-17 Formulações farmacêuticas contendo derivados de ácido lipóico BRPI0810439B1 (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US91260507P	2007-04-18	2007-04-18
US60/912.605		2007-04-18
PCT/US2008/060650 WO2008131114A2 (en)	2007-04-18	2008-04-17	Pharmaceutical formulations containing lipoic acid derivatives

Publications (2)

Publication Number	Publication Date
BRPI0810439A2 true BRPI0810439A2 (pt)	2014-10-07
BRPI0810439B1 BRPI0810439B1 (pt)	2021-06-29

Family

ID=39872894

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0810439-5A BRPI0810439B1 (pt)	2007-04-18	2008-04-17	Formulações farmacêuticas contendo derivados de ácido lipóico

Country Status (19)

Country	Link
US (4)	US20080262077A1 (pt)
EP (1)	EP2144609B1 (pt)
JP (1)	JP5480804B2 (pt)
KR (1)	KR101539785B1 (pt)
CN (1)	CN101820875B (pt)
AR (1)	AR067309A1 (pt)
AU (1)	AU2008242827B2 (pt)
BR (1)	BRPI0810439B1 (pt)
CA (1)	CA2684479C (pt)
CL (1)	CL2008001124A1 (pt)
ES (1)	ES2528414T3 (pt)
IL (1)	IL201581A (pt)
MX (1)	MX2009011165A (pt)
NZ (1)	NZ580973A (pt)
PL (1)	PL2144609T3 (pt)
PT (1)	PT2144609E (pt)
SA (1)	SA08290240B1 (pt)
TW (1)	TWI459944B (pt)
WO (1)	WO2008131114A2 (pt)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT2144609E (pt)	2007-04-18	2015-02-06	Cornerstone Pharmaceuticals Inc	Formulações farmacêuticas contendo derivados de ácido lipóico
EP2695614B1 (en) *	2007-04-18	2017-07-05	Cornerstone Pharmaceuticals, Inc.	Lipoic acid derivatives
US8263653B2 (en) *	2007-04-18	2012-09-11	Cornerstone Pharmaceuticals, Inc.	Pharmaceutical formulations containing lipoic acid derivatives
KR20110004846A (ko) *	2008-03-04	2011-01-14	로버트 쇼어	효소의 구조, 활성 및/또는 발현 정도의 조절
WO2009123597A1 (en) *	2008-04-04	2009-10-08	Robert Shorr	Pharmaceutical composition
EP2389178A4 (en) *	2008-12-01	2012-06-06	Invasc Therapeutic Inc	COMPOSITIONS CONTAINING INHIBITORS OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM AND LIPOIC ACID COMPOUNDS, AND THEIR USE FOR THE TREATMENT OF RENIN-ANGIOTENSIN-ALDOSTERONE ASSOCIATED DISORDERS
WO2010110771A2 (en) *	2009-03-25	2010-09-30	Frank Gibson	Substituted thiol-containing alkyl fatty acids and process for synthesizing derivatives thereof
EP3318248B1 (en)	2009-12-01	2019-04-10	Translate Bio, Inc.	Delivery of mrna for the augmentation of proteins and enzymes in human genetic diseases
WO2011143590A1 (en) *	2010-05-14	2011-11-17	Cornerstone Pharmaceuticals, Inc.	Combination therapy compositions and methods using lipoic acid derivatives and an anti-proliferation agent
WO2011143593A1 (en) *	2010-05-14	2011-11-17	Cornerstone Pharmaceuticals, Inc.	Conjugates of a lipoic acid derivative and anti-proliferation agent and medical uses thereof
BR112013031553A2 (pt)	2011-06-08	2020-11-10	Shire Human Genetic Therapies, Inc.	composições, mrna que codifica para uma hgla e seu uso, uso de pelo menos uma molécula de mrna e um veículo de transferência e uso de um mrna que codifica para proteína exógena
CN102657606B (zh) *	2012-05-25	2014-01-01	江苏神龙药业有限公司	一种供静脉给药用的硫辛酸注射液
EP3536787A1 (en)	2012-06-08	2019-09-11	Translate Bio, Inc.	Nuclease resistant polynucleotides and uses thereof
EP2934542A4 (en) *	2012-12-19	2016-08-10	Robert Shorr	PHARMACEUTICAL COMPOUNDS
KR102248744B1 (ko)	2013-03-14	2021-05-06	샤이어 휴먼 지네틱 테라피즈 인크.	Cftr mrna 조성물 및 관련 방법 및 사용
WO2014152966A1 (en)	2013-03-14	2014-09-25	Shire Human Genetic Therapies, Inc.	Methods for purification of messenger rna
CN103360437B (zh) *	2013-04-27	2015-10-21	江苏教育学院	一种硫辛酸糖类衍生物及其制备方法和在制备抗肿瘤药物中的应用
CN103497344B (zh) *	2013-09-25	2015-09-23	深圳先进技术研究院	用于负载贵金属颗粒的纳米凝胶及其制备方法与应用
MX381303B (es)	2013-10-22	2025-03-12	Shire Human Genetic Therapies	Composición que comprende un ácido ribonucleico mensajero que codifica argininosuccinato sintetasa para usarse en el tratamiento de la deficiencia de argininosuccinato sintetasa.
JP6506749B2 (ja)	2013-10-22	2019-04-24	シャイアーヒューマンジェネティックセラピーズインコーポレイテッド	フェニルケトン尿症のためのｍＲＮＡ療法
KR20250005450A (ko)	2014-04-25	2025-01-09	샤이어 휴먼 지네틱 테라피즈 인크.	메신저 rna 의 정제 방법
ES2747702T3 (es) *	2014-06-19	2020-03-11	Rafael Pharmaceuticals Inc	Compuestos farmacéuticos
EP3189033B1 (en)	2014-06-19	2020-08-05	Rafael Pharmaceuticals, Inc.	Pharmaceutical compounds
EA201991747A1 (ru)	2017-02-27	2020-06-04	Транслейт Био, Инк.	НОВАЯ КОДОН-ОПТИМИЗИРОВАННАЯ мРНК CFTR
EP3624824B1 (en)	2017-05-16	2024-07-10	Translate Bio, Inc.	Codon-optimized mrna encoding cftr for use in treating cystic fibrosis
WO2020041793A1 (en)	2018-08-24	2020-02-27	Translate Bio, Inc.	Methods for purification of messenger rna
WO2020106946A1 (en)	2018-11-21	2020-05-28	Translate Bio, Inc.	TREATMENT OF CYSTIC FIBROSIS BY DELIVERY OF NEBULIZED mRNA ENCODING CFTR
TW202114651A (zh) *	2019-08-16	2021-04-16	美商拉斐爾製藥公司	用於治療癌症之方法及含有４，６—雙（苄硫基）己酸之藥物組成物
US20230092232A1 (en) *	2020-02-28	2023-03-23	University Of Florida Research Foundation, Incorporated	Compounds that modulate anti-tumor immunity and methods of doing the same
CN116710072A (zh) *	2020-11-03	2023-09-05	基石制药股份有限公司	使用德维司他治疗胆道癌的治疗方法和组合物
CN119770650A (zh) *	2025-01-09	2025-04-08	华中科技大学	一种硫辛酸-胆碱离子液体溶液及其制备方法和应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2805251A (en) *	1953-07-22	1957-09-03	Ethyl Corp	Preparation of aryloxyaliphatic acids and salts thereof
GB758897A (en)	1953-10-19	1956-10-10	Merck & Co Inc	Thio-substituted aliphatic carboxylic acids and their preparation
US2809978A (en) *	1953-12-04	1957-10-15	Merck & Co Inc	Intermediates useful in the synthesis of alpha-lipoic acid
US3002011A (en) *	1953-12-04	1961-09-26	Merck & Co Inc	Intermediates and processes for producing alpha-lipoic acid
US2980716A (en) *	1954-06-11	1961-04-18	Research Corp	Method for preparing 6, 8-dihalooctanoic esters
US2975198A (en) *	1954-07-08	1961-03-14	Research Corp	Lipoic acid intermediates
US2852531A (en) *	1954-09-24	1958-09-16	Merck & Co Inc	Tris-(2-tetrahydropyranyl) esters of 6, 8-bis (hydrocarbonmercapto)-4, 4-dicarboxy-5-ocaprylic acid and preparation thereof
US2875238A (en) *	1957-02-19	1959-02-24	Merck & Co Inc	Intermediates useful in the synthesis of alpha-lipoic acid
US2875239A (en) *	1957-02-19	1959-02-24	Merck & Co Inc	Intermediates useful in the synthesis of alpha-lipoic acid
US2985685A (en) *	1959-01-26	1961-05-23	American Cyanamid Co	Alkanolamine aluminates as catalysts for ester redistribution
US3453312A (en) *	1966-04-27	1969-07-01	Merck & Co Inc	(beta - (substituted-thio) - acylphenoxy)-alkanoic acids and (beta-(substitutedthio) acylphenylmercapto) alkanoic acids and derivatives thereof
US3345368A (en) *	1967-02-15	1967-10-03	American Cyanamid Co	Substituted 7-acetylamino cephalosporanic acids
US3881017A (en) *	1973-05-18	1975-04-29	Ciba Geigy Corp	9-Thiaprostaglandin compositions
DE2422498A1 (de)	1973-05-18	1974-12-05	Ciba Geigy Ag	Neue thiaprostaglandine und verfahren zu ihrer herstellung
JPS5323539Y2 (pt) *	1973-11-30	1978-06-17
DE3512911A1 (de) *	1985-04-11	1986-10-16	Degussa Ag, 6000 Frankfurt	Verfahren zur herstellung von 1,2-dithiolan-3-pentansaeure (thioctsaeure)
US5344941A (en) *	1986-09-03	1994-09-06	Samour Carlos M	Water soluble salts of thionaphthene-2-carboxylic acid
DE4000397A1 (de) *	1990-01-09	1991-07-11	Hoechst Ag	Lipidselektive antioxidantien sowie deren herstellung und verwendung
US5569670A (en) *	1992-06-05	1996-10-29	Asta Medica Aktiengesellschaft	Combination medications containing alpha-lipoic acid and related
EP0692975A4 (en) *	1993-04-08	2000-11-29	Univ Queensland	ADMINISTRATION OF A VASO-ACTIVE AGENT AND A THERAPEUTIC AGENT
US5463093A (en) *	1993-11-26	1995-10-31	Garnett; Merrill	Palladium complexes and methods for using same in the treatment of tumors or Psoriasis
FR2777001B1 (fr) *	1998-04-01	2000-06-09	Cird Galderma	Derives de l'acide 6,8-dimercaptooctanoique substitues en 6-s et/ou en 8-s par le radical (3-methylthiopropanoyl) et compositions pharmaceutiques destinees au traitement des tumeurs cancereuses
EP1486495B1 (en) *	1998-10-26	2009-12-09	The Research Foundation of State University of New York	Salts of lipoic acid derivatives and their use in treatment of disease
US7320797B2 (en) *	2003-08-29	2008-01-22	Bioderm Research	Antiaging cosmetic delivery systems
JP2007077066A (ja) *	2005-09-14	2007-03-29	Shiseido Co Ltd	不全角化抑制剤、毛穴縮小剤
US20090036356A1 (en) *	2006-03-06	2009-02-05	Avestha Gengraine Technologies Pvt. Ltd.	Octanoic acid derivatives as dipeptidyl peptidase inhibitors
EP2695614B1 (en) *	2007-04-18	2017-07-05	Cornerstone Pharmaceuticals, Inc.	Lipoic acid derivatives
US8263653B2 (en) *	2007-04-18	2012-09-11	Cornerstone Pharmaceuticals, Inc.	Pharmaceutical formulations containing lipoic acid derivatives
PT2144609E (pt)	2007-04-18	2015-02-06	Cornerstone Pharmaceuticals Inc	Formulações farmacêuticas contendo derivados de ácido lipóico

2008
- 2008-04-17 PT PT87805388T patent/PT2144609E/pt unknown
- 2008-04-17 ES ES08780538.8T patent/ES2528414T3/es active Active
- 2008-04-17 JP JP2010504247A patent/JP5480804B2/ja not_active Expired - Fee Related
- 2008-04-17 CN CN200880017628.5A patent/CN101820875B/zh not_active Expired - Fee Related
- 2008-04-17 CA CA2684479A patent/CA2684479C/en active Active
- 2008-04-17 US US12/105,100 patent/US20080262077A1/en not_active Abandoned
- 2008-04-17 EP EP08780538.8A patent/EP2144609B1/en not_active Not-in-force
- 2008-04-17 BR BRPI0810439-5A patent/BRPI0810439B1/pt not_active IP Right Cessation
- 2008-04-17 KR KR1020097023900A patent/KR101539785B1/ko not_active Expired - Fee Related
- 2008-04-17 AU AU2008242827A patent/AU2008242827B2/en not_active Ceased
- 2008-04-17 NZ NZ580973A patent/NZ580973A/en not_active IP Right Cessation
- 2008-04-17 PL PL08780538T patent/PL2144609T3/pl unknown
- 2008-04-17 MX MX2009011165A patent/MX2009011165A/es active IP Right Grant
- 2008-04-17 WO PCT/US2008/060650 patent/WO2008131114A2/en not_active Ceased
- 2008-04-18 TW TW097114308A patent/TWI459944B/zh not_active IP Right Cessation
- 2008-04-18 CL CL2008001124A patent/CL2008001124A1/es unknown
- 2008-04-18 AR ARP080101607A patent/AR067309A1/es not_active Application Discontinuation
- 2008-04-19 SA SA08290240A patent/SA08290240B1/ar unknown
2009
- 2009-10-15 IL IL201581A patent/IL201581A/en active IP Right Grant
2011
- 2011-10-05 US US13/253,503 patent/US8691873B2/en active Active
2014
- 2014-03-27 US US14/227,148 patent/US9320726B2/en not_active Expired - Fee Related
2016
- 2016-04-21 US US15/134,896 patent/US9872845B2/en active Active

Also Published As

Publication number	Publication date
TW200901964A (en)	2009-01-16
JP5480804B2 (ja)	2014-04-23
IL201581A (en)	2016-04-21
SA08290240B1 (ar)	2012-02-22
IL201581A0 (en)	2010-05-31
WO2008131114A3 (en)	2010-01-21
JP2010524963A (ja)	2010-07-22
AR067309A1 (es)	2009-10-07
KR101539785B1 (ko)	2015-07-27
PT2144609E (pt)	2015-02-06
EP2144609B1 (en)	2014-10-29
US20170056355A1 (en)	2017-03-02
US20120178812A1 (en)	2012-07-12
AU2008242827A1 (en)	2008-10-30
EP2144609A2 (en)	2010-01-20
WO2008131114A2 (en)	2008-10-30
US20150011633A1 (en)	2015-01-08
CA2684479A1 (en)	2008-10-30
EP2144609A4 (en)	2010-06-16
US8691873B2 (en)	2014-04-08
US20080262077A1 (en)	2008-10-23
ES2528414T3 (es)	2015-02-10
PL2144609T3 (pl)	2015-04-30
HK1140424A1 (en)	2010-10-15
CA2684479C (en)	2017-11-14
BRPI0810439B1 (pt)	2021-06-29
KR20100029744A (ko)	2010-03-17
MX2009011165A (es)	2009-12-09
TWI459944B (zh)	2014-11-11
NZ580973A (en)	2011-10-28
US9320726B2 (en)	2016-04-26
US9872845B2 (en)	2018-01-23
CN101820875A (zh)	2010-09-01
AU2008242827B2 (en)	2014-06-05
CL2008001124A1 (es)	2009-01-02
CN101820875B (zh)	2014-07-23

Publication	Publication Date	Title
BRPI0810439A2 (pt)	2014-10-07	Formulações farmacêuticas contendo derivados de ácido lipóico
BRPI0810660A2 (pt)	2014-10-07	Derivados do ácido lipóico
BRPI0820381A2 (pt)	2015-05-19	Formulações farmacêuticas
NO20090578A (no)	2009-03-09	Farmasøytisk sammensetning inneholdende en tetrahydrofolsyre
LTPA2018005I1 (lt)	2018-02-12	Farmacinė kompozicija
DK2346495T4 (da)	2023-08-28	Farmaceutisk formulering 514
DK2328601T3 (da)	2020-04-14	Linaclotid-holdige formuleringer til oral indgivelse
BRPI0821474A2 (pt)	2017-05-09	formulação farmacêutica líquida estável
ITBO20050123A1 (it)	2005-06-06	Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
BRPI0721651A2 (pt)	2014-04-01	Composição farmacêutica
DK2966175T3 (da)	2019-07-01	Farmaceutiske sammensætninger indeholdende cortexolon-17-alpha-propionat
DK3492069T3 (da)	2022-03-14	Farmaceutiske sammensætninger omfattende jern-oxy-hydroxid
DK2391349T3 (da)	2014-11-03	Farmaceutisk sammensætning omfattende 2-oco-1-pyrrolidin-derivater
DK2120884T3 (da)	2011-02-07	Farmaceutisk sammensætning
BRPI0921654A2 (pt)	2016-02-10	formulação farmacêutica
DK2391351T3 (da)	2014-12-01	Farmaceutisk sammensætning omfattende 2-oxo-1-pyrrolidinderivater
PT2209464E (pt)	2014-09-05	Composição farmacêutica antimalárica
BRPI0820198A2 (pt)	2019-09-24	composições farmacêuticas
BRPI0806938A2 (pt)	2014-05-06	Composição farmacêutica contedo um derivado de camptotecina
BRPI0818702A2 (pt)	2015-04-22	Formulação farmacêutica de ácido clavulânico
BRPI0912656A2 (pt)	2016-01-26	formulação farmacêutica sólida
DK2182920T3 (da)	2013-03-04	Stabil væskeformig farmaceutisk komposition baseret på trazodon
BRPI0814800A2 (pt)	2015-02-03	Derivados de aminoácidos
NO20084860L (no)	2009-01-08	Stabile farmasøytiske preparater av 2-aza-bisyklo-[3,3,0]-oktan-3-karboksylsyrederivater
BRPI0913709A2 (pt)	2015-10-13	"formulação farmacêutica"

Legal Events

Date	Code	Title	Description
2017-10-10	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2018-04-17	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2019-02-12	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]	Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI
2019-04-09	B07A	Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
2019-08-13	B09B	Patent application refused [chapter 9.2 patent gazette]
2019-10-29	B12B	Appeal against refusal [chapter 12.2 patent gazette]
2021-06-29	B16A	Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]	Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 17/04/2008, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, , QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.
2025-02-11	B21F	Lapse acc. art. 78, item iv - on non-payment of the annual fees in time	Free format text: REFERENTE A 17A ANUIDADE.
2025-07-15	B24J	Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)	Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2823 DE 11-02-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.